Singer Capital Markets is delighted to announce its appointment as Nominated Adviser and UK Broker to Verona Pharma plc with immediate effect.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.
Ticker: AIM: VRP | NASDAQ: VRNA
Current Market Cap: £63 million*
Website: Click Here
*As at 01/05/2019
[follow align=”center” twitter=”https://twitter.com/nplus1singer” linkedin=”https://www.linkedin.com/company/274452/”]